Bivalent COVID-19 Boosters Superior To Monovalent Vaccines For Protection Against Omicron Infection, Study Finds

Infectious Disease Advisor (6/11, Nye) reports, “Bivalent COVID-19 booster vaccines are superior to the original monovalent vaccines for protection against severe Omicron-associated outcomes, according to study results published in Vaccine.” In the study, “across all age groups, the updated bivalent booster vaccines showed superior effectiveness against symptomatic and asymptomatic Omicron infection when compared with both 2 or more (VE, 30.8%; 95% CI, 22.5-38.2; I2 =99.4%) and 3 or more (VE, 41.8%; 95% CI, 9.0-62.8; I2 =99.7%) monovalent doses. In 2 studies comprising unvaccinated patients as the reference group, the bivalent boosters were associated with a combined VE of 53.5% (95% CI, -22.2 to 82.3; I2 =96.4%).”